LABORATORIO FARMACEUTICO ERFO S.P.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.13 EUR | 0.00% |
|
+0.89% | -13.74% |
| 03-29 | Laboratorio Farmaceutico Erfo, revenues grow and profit remains stable | AN |
| 02-19 | Mib in the red at 31,600; TIM still on top | AN |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -13.74% | 10.96M | - | ||
| +33.43% | 700B | C+ | ||
| +27.45% | 569B | B | ||
| -5.12% | 358B | C+ | ||
| +19.59% | 330B | B- | ||
| +4.89% | 287B | C+ | ||
| +15.98% | 236B | B+ | ||
| +6.70% | 202B | B- | ||
| -9.41% | 197B | A+ | ||
| +4.26% | 161B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ERFO Stock
- Ratings Laboratorio Farmaceutico Erfo S.p.A.